Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kentaro Takeda

Showing results (11-20 of 64) with videos related to

Pageof 7
Sort By:
Journal of Pharmacological Sciences|December 3, 2013
Combination effects of ZSET1446/ST101 with memantine on cognitive function and extracellular acetylcholine in the hippocampusYoshimasa Yamaguchi, Kentaro Takeda, Masataka Hino
Biometrical Journal. Biometrische Zeitschrift|May 13, 2022
gBOIN-ET: The generalized Bayesian optimal interval design for optimal dose-finding accounting for ordinal graded efficacy and toxicity in early clinical trialsKentaro Takeda, Satoshi Morita, Masataka Taguri
Pharmaceutical Statistics|March 10, 2025
BF-BOIN-ET: A Backfill Bayesian Optimal Interval Design Using Efficacy and Toxicity Outcomes for Dose OptimizationKentaro Takeda, Jing Zhu, Akihiro Hirakawa
Pharmaceutical Statistics|December 13, 2019
TITE-BOIN-ET: Time-to-event Bayesian optimal interval design to accelerate dose-finding based on both efficacy and toxicity outcomesKentaro Takeda, Satoshi Morita, Masataka Taguri
Pharmaceutical Statistics|August 2, 2018
Bayesian dose-finding phase I trial design incorporating pharmacokinetic assessment in the field of oncologyKentaro Takeda, Kanji Komatsu, Satoshi Morita
Pharmaceutical Statistics|September 27, 2022
An adaptive biomarker basket design in phase II oncology trialsShufang Liu, Kentaro Takeda, Alan Rong
Clinical and Translational Science|August 4, 2025
Retrospective Analysis of Master Protocols in Tumor-Agnostic Drug Development: Evaluation of Application to Single-Agent Therapies With ORR as the Endpoint for Approval of Oncology DrugsKeiko Yamamoto, Kentaro Takeda, Hideki Maeda
Pharmaceutical Statistics|January 24, 2017
A simulation study of methods for selecting subgroup-specific doses in phase 1 trialsSatoshi Morita, Peter F Thall, Kentaro Takeda
Pharmaceutical Statistics|December 4, 2021
TITE-gBOIN: Time-to-event Bayesian optimal interval design to accelerate dose-finding accounting for toxicity gradesKentaro Takeda, Qing Xia, Shufang Liu, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 19, 2015
Potentiation of Acetylcholine-Mediated Facilitation of Inhibitory Synaptic Transmission by an Azaindolizione Derivative, ZSET1446 (ST101), in the Rat HippocampusKentaro Takeda, Yoshimasa Yamaguchi, Masataka Hino, et al.
Pageof 7

Showing results (11-20 of 64) with videos related to

Sort By:
Pageof 7
Journal of Pharmacological Sciences|December 3, 2013
Combination effects of ZSET1446/ST101 with memantine on cognitive function and extracellular acetylcholine in the hippocampusYoshimasa Yamaguchi, Kentaro Takeda, Masataka Hino
Biometrical Journal. Biometrische Zeitschrift|May 13, 2022
gBOIN-ET: The generalized Bayesian optimal interval design for optimal dose-finding accounting for ordinal graded efficacy and toxicity in early clinical trialsKentaro Takeda, Satoshi Morita, Masataka Taguri
Pharmaceutical Statistics|March 10, 2025
BF-BOIN-ET: A Backfill Bayesian Optimal Interval Design Using Efficacy and Toxicity Outcomes for Dose OptimizationKentaro Takeda, Jing Zhu, Akihiro Hirakawa
Pharmaceutical Statistics|December 13, 2019
TITE-BOIN-ET: Time-to-event Bayesian optimal interval design to accelerate dose-finding based on both efficacy and toxicity outcomesKentaro Takeda, Satoshi Morita, Masataka Taguri
Pharmaceutical Statistics|August 2, 2018
Bayesian dose-finding phase I trial design incorporating pharmacokinetic assessment in the field of oncologyKentaro Takeda, Kanji Komatsu, Satoshi Morita
Pharmaceutical Statistics|September 27, 2022
An adaptive biomarker basket design in phase II oncology trialsShufang Liu, Kentaro Takeda, Alan Rong
Clinical and Translational Science|August 4, 2025
Retrospective Analysis of Master Protocols in Tumor-Agnostic Drug Development: Evaluation of Application to Single-Agent Therapies With ORR as the Endpoint for Approval of Oncology DrugsKeiko Yamamoto, Kentaro Takeda, Hideki Maeda
Pharmaceutical Statistics|January 24, 2017
A simulation study of methods for selecting subgroup-specific doses in phase 1 trialsSatoshi Morita, Peter F Thall, Kentaro Takeda
Pharmaceutical Statistics|December 4, 2021
TITE-gBOIN: Time-to-event Bayesian optimal interval design to accelerate dose-finding accounting for toxicity gradesKentaro Takeda, Qing Xia, Shufang Liu, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 19, 2015
Potentiation of Acetylcholine-Mediated Facilitation of Inhibitory Synaptic Transmission by an Azaindolizione Derivative, ZSET1446 (ST101), in the Rat HippocampusKentaro Takeda, Yoshimasa Yamaguchi, Masataka Hino, et al.
Pageof 7